FDA Expands Marstacimab Indication in Hemophilia A and B - Top-Institutions - MDSpire

FDA Expands Marstacimab Indication in Hemophilia A and B

Phase 3 BASIS and BASIS KIDS data supported the expanded indication across pediatric and inhibitor populations.

  • By

  • Kathryn Wighton

  • June 8, 2026

  • 3 min

Share

Top Institutions in Pediatrics

Brief introduction explaining scope and methodology.

  • #1

    McMaster University/Hamilton Health Sciences
    McMaster University/Hamilton Health Sciences

    Hamilton, Ontario

    Key Differentiators

    • Hematology
    • Thrombosis

  • #2

    Northwell Health Hemostasis & Thrombosis Center
    Northwell Health Hemostasis & Thrombosis Center

    New Hyde Park, New York

    Key Differentiators

    • Hematology
    • Thrombosis

Original Source(s)

FDA Expands Marstacimab Indication in Hemophilia A and B

  • by Kathryn Wighton

  • June 8, 2026

Related Content

Risk of drug-related aggression in pediatric populations: a pharmacovigilance analysis using the FAERS database

Explainable machine learning unveils the key role of cooperation ability in school bullying and its gender-differentiated impact on cooperative atmosphere

Can Finerenone Alter Glomerular Disease Trajectory?

A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases.